leadf
logo-loader
viewNemaura Medical Inc

Nemaura Medical banks $18M in cash to fund commercialization of its diabetes diagnostic devices and subscription services

The UK-based company has developed its continuous glucose monitor sugarBEAT and health subscription service BEATdiabetes

Nemaura Medical Inc - Nemaura Medical Inc has about $18 million in cash to help fund commercialization of its diabetes diagnostic devices and subscription services
Nemaura strengthened its financial position by reducing research and development as well as general and administrative expenses in its first quarter

Nemaura Medical Inc (NASDAQ:NMRD) announced Monday that it has about $18 million in cash to help fund the development and commercialization of its diabetes diagnostic devices and subscription services.  

The company said it ended its first quarter on June 30, 2020, with $5.9 million in cash but raised an additional $10.7 million a month later via a fundraising scheme. 

Nemaura also noted that it further strengthened its financial position heading into its current second quarter by reducing research and development as well as general and administrative expenses in April, May and June. During its first-quarter, it also narrowed its comprehensive loss to $1.095 million compared to a loss of $1.267 million in the year-ago quarter. 

READ: Nemaura Medical enters into LOI to acquire diabetes-care firm Healthimation to 'complement' proBeat service

“We continue to make significant strides towards our commercial goals of diabetes prevention and management, and this quarter we secured sufficient capital to support our planned product launch in the USA, UK and Germany, demonstrating investor confidence in the company, its management and its product pipeline,” Nemaura CEO Faz Chodhury said in a statement.

Nemaura, based in Loughborough, is developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT, its non-invasive and flexible continuous glucose monitor.

The devices and sugarBEAT are offered in conjunction with BEATdiabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Nemaura Medical Inc

Price: 4.14 USD

NASDAQ:NMRD
Market: NASDAQ
Market Cap: $94.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Nemaura Medical reveals details of upcoming European launch...

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Dr...

on 10/08/2019

2 min read